<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_Tuebingen skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:Tuebingen/</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><P>This year we want to develop a pathogen-specific antibiotic to circumvent the possible establishment of resistance and side-effects during therapy.
</P><P>We develop a novel sidechain for Clorobiocin via chemical synthesis and a newly designed enzyme expressed in Streptomyces.
</P><P>This antibiotic will be used in toxicity assays in E. coli with novobiocin resistent gyrases, which could later be used in the treatment of MRSA.
</P></DIV></DIV></DIV></DIV></DIV></BODY></HTML>